Last reviewed · How we verify
NCT06676943: eXcision
Investigating the Diagnostic Performance of High-resolution Specimen PET-CT in Determining Margin Status in Cancer Resection
NA trial testing XEOS AURA 10 specimen PET-CT scan of tumour specimens in Prostate Cancer Surgery in 57 participants. Completed in 28 August 2025.
28 August 2025
Quick facts
| Lead sponsor | University Hospitals Coventry and Warwickshire NHS Trust |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 57 |
| Start date | 20 September 2024 |
| Primary completion | 28 August 2025 |
| Estimated completion | 28 August 2025 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- XEOS AURA 10 specimen PET-CT scan of tumour specimens
Conditions studied
- Prostate Cancer Surgery — all drugs for Prostate Cancer Surgery →
- Head and Neck Cancers — all drugs for Head and Neck Cancers →
Sponsor
University Hospitals Coventry and Warwickshire NHS Trust
Who can join
18 and older, any sex, with Prostate Cancer Surgery or Head and Neck Cancers. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Surgical removal is the treatment for many different cancers. Patient outcomes depend on complete cancer removal with no tumour present at the edge of the section removed (specimen). If cancer is left behind, then patients might need additional cancer treatment. Regardless of whether extra treatment is required, knowing that removal was incomplete causes anxiety. The need for a wide removal of the tumour must be balanced against the harm caused by more extensive surgery particularly when important organs and structures are close by. The fact that the cancer is not visible to the surgeon during the operation means that there is an element of guesswork when deciding how much tissue to remove. This study is examining a technique that the investigators hope will provide surgeons with more precise information about how much tissue to remove during cancer operations using a new type of Positron Emission Tomography-Computed Tomography (PET-CT) scanner. Patients with different types of cancer (e.g. prostate, head and neck cancer) will be injected with a small amount of radioactive tracer at the beginning of their cancer operation. This tracer will attach itself to the cancer cells. Once the surgical specimen is removed it will be placed into the specimen PET-CT scanner so that the surgeon can see the cancer within the specimen. The investigators will then compare the results of the scan of the specimen taken during the operation with the results when the whole specimen has been examined under the microscope. Examination under the microscope is considered to be the gold standard for deciding whether the cancer removal operation has been successful. This study aims to tell us how accurate the new specimen PET-CT scanner results are, and so whether or not surgeons can rely on the results to guide them during operations in the future.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06676943
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate Cancer Surgery
Currently open trials in the same condition.
- NCT06822452 — Prospective Comparative Study Evaluating the Early Complications of Robot-assisted Radical Prostatectomy Performed as an · NA · recruiting
- NCT06835426 — High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins · NA · recruiting
Other University Hospitals Coventry and Warwickshire NHS Trust trials
Trials by the same sponsor.
- NCT07353255 — Fibrescope vs Videolaryngoscope for Nasotracheal Intubation · NA · not yet recruiting
- NCT06937983 — Optimised Decrement Evoked Potential (DeEP) Mapping to Guide Ventricular Tachycardia (VT) Ablation in Patients With Stru · NA · recruiting
- NCT06483308 — Shortened High-dose Palliative Radiotherapy for Lung Cancer · NA · active not recruiting
- NCT07014033 — Single-use Versus Multiple-use Endoscopes in Gastroenterology · recruiting
- NCT06159868 — Physiotherapy and Optimised Nutrition in Survivors of Critical Illness · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06676943 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospitals Coventry and Warwickshire NHS Trust
- Last refreshed: 13 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06676943.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing